Purple Biotech Ltd (PPBT)

0.4900 +0.0366 (+8.07%) At close: 04:00PM EDT

Purple Biotech Ltd

4 Oppenheimer Street
Science Park
Rehovot 7670104
Israel
972 3 933 3121
https://purple-biotech.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 20

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Gil Efron CPA, M.A.	Chief Executive Officer	455.44k	N/A	1966
Dr. Michael Schickler Ph.D.	Head of Clinical & Regulatory Affairs	264.98k	N/A	1958
Mr. Lior Fhima CPA, M.B.A.	Chief Financial Officer	N/A	N/A	1977
Mr. Ido Morpurgo B.Sc., L.L.M.	Vice President of Operations	N/A	N/A	1972

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.

Corporate governance

Purple Biotech Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.